Scalper1 News
Aduro Biotech (ADRO) soared on its initial public offering, one of three biotech IPOs Wednesday. Aduro, a developer of cancer immunotherapy treatments, priced at 17 and opened at 32. It raised $119 million, pricing 7 million shares at 17. The stock was trading up 113% to 36.25 in afternoon trading on the stock market today . Existing shareholders in Aduro include a venture capital unit of Johnson & Johnson (JNJ). The group, called Johnson & Johnson Scalper1 News
Scalper1 News